-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised ivacaftor,
lumacaftor+ivacaftor, tezacaftor+ivacaftor and
elexacaftor+tezacaftor+ivacaftor for patients with cystic fibrosis (CF).

CF and listing dates

CF is a condition that affects the cells that produce mucus, sweat and
digestive juices. It causes these fluids to become thick and sticky.
They then plug up tubes, ducts and passageways leading to airway and
digestive issues.

Listing dates:

-   ivacaftor - 1 December 2014
-   lumacaftor+ivacaftor - 1 October 2018
-   tezacaftor+ivacaftor - 1 December 2019
-   elexacaftor+tezacaftor+ivacaftor - 1 April 2022

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to the PBS - Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page has links to application forms, contact details, item
and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing and National Demand Allocation (PaNDA)

Processing written authority approval requests

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
